Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K.

Clin Pharmacol Ther. 2006 Aug;80(2):192-201.

PMID:
16890580
2.

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.

Koo DH, Ryu MH, Ryoo BY, Beck MY, Na YS, Shin JG, Lee SS, Kim EY, Kang YK.

Cancer Chemother Pharmacol. 2015 Jan;75(1):173-82. doi: 10.1007/s00280-014-2630-6. Epub 2014 Nov 23.

PMID:
25417047
3.

Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.

Ther Drug Monit. 2011 Apr;33(2):244-50. doi: 10.1097/FTD.0b013e31820beb02.

PMID:
21311410
4.

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.

Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR.

Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31.

PMID:
23117072
5.

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.

Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, Saitoh H, Fujishima N, Yoshioka T, Hirokawa M, Sawada K.

J Hum Genet. 2010 Nov;55(11):731-7. doi: 10.1038/jhg.2010.98. Epub 2010 Aug 19.

PMID:
20720558
6.

Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.

Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R.

Biomed Pharmacother. 2014 Apr;68(3):343-9. doi: 10.1016/j.biopha.2014.01.009. Epub 2014 Feb 7.

PMID:
24581936
7.
8.

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL.

Clin Cancer Res. 2003 Aug 15;9(9):3246-53.

9.

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K.

Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9.

PMID:
15970668
10.

Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.

Skoglund K, Boiso Moreno S, Jönsson JI, Vikingsson S, Carlsson B, Gréen H.

Pharmacogenet Genomics. 2014 Jan;24(1):52-61. doi: 10.1097/FPC.0000000000000022.

PMID:
24322003
11.

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD.

Cancer Biol Ther. 2007 Mar;6(3):432-8. Epub 2007 Mar 29.

PMID:
17312388
12.

The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.

Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR.

Clin Cancer Res. 2007 Apr 15;13(8):2463-70.

13.

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.

Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.

Clin Cancer Res. 2005 Oct 15;11(20):7398-404.

14.
15.

Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.

Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H.

Clin Pharmacol Ther. 2007 Jul;82(1):33-40. Epub 2007 May 9.

PMID:
17495881
16.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

17.

Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.

Théou N, Gil S, Devocelle A, Julié C, Lavergne-Slove A, Beauchet A, Callard P, Farinotti R, Le Cesne A, Lemoine A, Faivre-Bonhomme L, Emile JF.

Clin Cancer Res. 2005 Nov 1;11(21):7593-8.

18.

Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.

Takahashi N, Miura M.

Pharmacology. 2011;87(5-6):241-8. doi: 10.1159/000324900. Epub 2011 Apr 6. Review.

19.

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Séronie-Vivien S, LeCesne A, Vassal G; Innovative Therapies with Children with Cancer European consortium..

Clin Cancer Res. 2008 Nov 1;14(21):7102-9. doi: 10.1158/1078-0432.CCR-08-0950.

20.

Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.

Wan Z, Wang G, Li T, Xu B, Pei Q, Peng Y, Sun H, Cheng L, Zeng Y, Yang G, Zhu YS.

J Pharmacol Exp Ther. 2015 Sep;354(3):310-5. doi: 10.1124/jpet.115.225045. Epub 2015 Jun 16.

Supplemental Content

Support Center